208 related articles for article (PubMed ID: 31680850)
1. CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease.
Karami A; Eriksdotter M; Kadir A; Almkvist O; Nordberg A; Darreh-Shori T
Front Mol Neurosci; 2019; 12():239. PubMed ID: 31680850
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Grut M; Strandberg B; Ringheim A; B Eriksson ; Blomquist G; Långström B; Nordberg A
Neurobiol Aging; 2008 Aug; 29(8):1204-17. PubMed ID: 17379359
[TBL] [Abstract][Full Text] [Related]
4. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
6. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
Moss DE; Perez RG
Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
[TBL] [Abstract][Full Text] [Related]
7. Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway.
Vijayaraghavan S; Karami A; Aeinehband S; Behbahani H; Grandien A; Nilsson B; Ekdahl KN; Lindblom RP; Piehl F; Darreh-Shori T
PLoS One; 2013; 8(6):e65936. PubMed ID: 23840379
[TBL] [Abstract][Full Text] [Related]
8. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
9. Galantamine: a review of its use in Alzheimer's disease.
Scott LJ; Goa KL
Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
[TBL] [Abstract][Full Text] [Related]
10. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
[TBL] [Abstract][Full Text] [Related]
11. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
Tariot PN
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
[TBL] [Abstract][Full Text] [Related]
12. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats.
Tomassoni D; Catalani A; Cinque C; Di Tullio MA; Tayebati SK; Cadoni A; Nwankwo IE; Traini E; Amenta F
Curr Alzheimer Res; 2012 Jan; 9(1):120-7. PubMed ID: 22191561
[TBL] [Abstract][Full Text] [Related]
13. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
14. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
16. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
Maelicke A
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
18. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.
Albuquerque EX; Santos MD; Alkondon M; Pereira EF; Maelicke A
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S19-25. PubMed ID: 11669505
[TBL] [Abstract][Full Text] [Related]
19. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
Darreh-Shori T; Soininen H
Curr Alzheimer Res; 2010 Feb; 7(1):67-73. PubMed ID: 20205672
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
